Skip to main content
. Author manuscript; available in PMC: 2019 Jan 7.
Published in final edited form as: Cell Rep. 2018 Sep 4;24(10):2643–2657. doi: 10.1016/j.celrep.2018.08.002

Figure 7. PRMT5 and PARP inhibitors synergistically target leukemia cells.

Figure 7.

(A) Multiplex immunoblots with Rme2s, PRMT5, and GAPDH in the indicated human leukemia cell lines before and after treatment with increasing doses of GSK3186000A (PRMT5i) for 4 days, showing decreasing levels of arginine methylation.

(B) Excess Over Bliss plots (Bliss method) showing synergistic effects between PRMT5i and the PARP inhibitor Olaparib (PARPi). Cells were treated with increasing amounts of PRMT5i, PARPi, or both combined at 1:1 ratio and cell viability was assessed with the CellTiter Glo method after 4 days of treatment.

(C) Colony forming units after treatment of normal cord blood derived CD34+ cells and the AML cell line MV4-11 with DMSO (control), PRMT5i, PARPi or a combination of PRMT5i and PARPi at the indicated concentrations. Left: representative pictures of colonies on semi-solid methylcellulose media. Scale bar, 1 mm. Right: Quantification of the number of colonies as percent of colonies compared to DMSO, 7 days after plating. *** P<0.0001 (one-way ANOVA Tukey’s multiple comparisons test, Adjusted P values).

See also Figure S7.